IPC분류정보
| 국가/구분 |
United States(US) Patent
등록
|
| 국제특허분류(IPC7판) |
|
| 출원번호 |
UP-0184528
(2005-07-19)
|
| 등록번호 |
US-7605123
(2009-11-10)
|
|
발명자
/ 주소 |
- Radhakrishnan, Balasingam
- Aggarwal, Diti
- Ferro, Michelle
- James, Kenneth D.
- Malkar, Navdeep B.
- Miller, Mark A.
- Pavliv, Leo
- Polowy, Karen
- Puskas, Monica
- Ekwuribe, Nnochiri N.
|
| 출원인 / 주소 |
|
| 대리인 / 주소 |
|
| 인용정보 |
피인용 횟수 :
16 인용 특허 :
206 |
초록
▼
Fatty acid compositions for administration of of pharmaceutical agents, such as proteins and peptides, protein and peptide conjugates, and/or cation-polypeptide conjugate complexes. In particular, the invention provides a solid pharmaceutical composition formulated for oral administration by ingesti
Fatty acid compositions for administration of of pharmaceutical agents, such as proteins and peptides, protein and peptide conjugates, and/or cation-polypeptide conjugate complexes. In particular, the invention provides a solid pharmaceutical composition formulated for oral administration by ingestion, having from about 0.1 to about 75% w/w fatty acid component, where the fatty acid component comprises saturated or unsaturated C4, C5, C6, C7, C8, C9, C10, C11, or C12 fatty acids and/or salts of such fatty acids; and a therapeutic agent. Further, the invention provides a liquid pharmaceutical composition formulated for oral administration by ingestion, comprising: from about 0.1 to about 10% w/v fatty acid component, where the fatty acid component comprises saturated or unsaturated C4, C5, C6, C7, C8, C9, C10, C11, or C12 fatty acids and/or salts of such fatty acids; and a therapeutic agent.
대표청구항
▼
We claim: 1. A water soluble solid pharmaceutical composition formulated for oral administration by ingestion, comprising: (a) from about 5 to about 65% w/w of a salt of a fatty acid component, where the salt of a fatty acid component comprises saturated or unsaturated C4, C5, C6, C7, C8, C9, C10,
We claim: 1. A water soluble solid pharmaceutical composition formulated for oral administration by ingestion, comprising: (a) from about 5 to about 65% w/w of a salt of a fatty acid component, where the salt of a fatty acid component comprises saturated or unsaturated C4, C5, C6, C7, C8, C9, C10, C11, or C12 fatty acids; and (b) an insulin compound conjugate comprising an insulin protein coupled to a modifying moiety having a formula: --X--R1--Y-PAG-Z-R2 (Formula VI) where, X, Y and Z are independently selected linking groups and each is optionally present, and X, when present, is coupled to the insulin compound by a covalent bond, wherein the linking group is selected from--C(O)--,--O--,--S--,--C--and--N--, R1, if present, is a lower alkyl and may optionally include a carbonyl group; R2 is selected from the group consisting of a lower alkyl, optionally including a carbonyl group, and a capping group selected from the group consisting of--CH3,--H, tosylate, branched or linear C1-6 and an activating group, wherein when R1 present, R2 is a member of the capping group; and PAG is a linear or branched carbon chain incorporating one or more polyethylene glycol moieties, and optionally incorporating one or more additional moieties selected from the group consisting of--S--,--O--,--N--, and--C(O)--; and an enteric coating material for coating of the water soluble solid composition fabricated into a solid form to survive passage through the stomach without substantial loss of the insulin protein. 2. The pharmaceutical composition of claim 1 comprising from about 40 to about 60% w/w of the salt of a fatty acid component. 3. The pharmaceutical composition of claim 1 where the insulin compound conjugated is complexed. 4. The pharmaceutical composition of claim 1 comprising a diluent selected from the group consisting of binders, disintegrants, fillers, diluents, lubricants, glidants, flow enhancers, compression aids, colors, sweeteners, preservatives, suspensing agents, dispersing agents, film formers, coatings, flavors, printing inks, celluloses, sugars, mannitols, lactoses, dissolution enhancers, and crosscarmaloses. 5. The pharmaceutical composition of claim 1 prepared in a form selected from the group consisting of tablets, minitabs, powders, hard gelatin capsules, or soft gelatin capsules. 6. The pharmaceutical composition of claim 1, wherein the salt of the fatty acid component is selected from salt of capric acid, salt of lauric acid and combination thereof. 7. The pharmaceutical composition of claim 1 comprising a buffer salt selected from the group consisting of phosphate buffer, sodium phosphate, tris buffer, citric acid buffer, and ethanolamine buffer. 8. The pharmaceutical composition of claim 1 comprising a buffer salt selected to achieve a buffering capacity at the site of absorption to maintain a local pH of from about 5 to about 8. 9. The pharmaceutical composition of claim 1 where the insulin compound conjugate consists of human insulin coupled at A1, B1 and/or B29 to a modifying moiety having a structure: 10. The pharmaceutical composition of claim 1 where the insulin compound conjugate consists of human insulin coupled at B29 to a modifying moiety having a structure: 11. The pharmaceutical composition of claim 1 where the insulin compound conjugate consists of human insulin coupled at A1, B1 and/or B29 to a modifying moiety having a structure: 12. The pharmaceutical composition of claim 1 where the modifying moiety has a structure: 13. The pharmaceutical composition of claim 1 where the insulin compound conjugate is coupled at A1, B1 and/or B29 to a linear or branched PEG moiety having from 2 to 15 PEG or from 2 to 10 PEG subunits. 14. The pharmaceutical composition of claim 1 wherein the insulin compound conjugate is complexed with zinc. 15. The pharmaceutical composition of claim 14 wherein the water solubility of the insulin compound conjugate is decreased by addition of the zinc.
※ AI-Helper는 부적절한 답변을 할 수 있습니다.